{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:17:31Z","timestamp":1768475851315,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eclinm.2025.103282","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T16:47:12Z","timestamp":1749055632000},"page":"103282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial"],"prefix":"10.1016","volume":"84","author":[{"given":"Jhingook","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-6431","authenticated-orcid":false,"given":"Yeong Hak","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sehhoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeong Jeong","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Ho","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Kwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Soo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Ill","family":"Zo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Mog","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinseon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-La","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joungho","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soohyun","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eclinm.2025.103282_bib1","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","article-title":"Recurrence-free survival in patients with surgically resected non-small cell lung cancer: a systematic literature review and meta-analysis","volume":"165","author":"Rajaram","year":"2024","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103282_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jtho.2018.10.002","article-title":"Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese joint committee of lung cancer registry database in 2010","volume":"14","author":"Okami","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103282_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 world Health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103282_bib4","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.jtho.2016.06.014","article-title":"The clinical impact of solid and micropapillary patterns in resected lung adenocarcinoma","volume":"11","author":"Yanagawa","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.eclinm.2025.103282_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2022.04.005","article-title":"Prognostic impact of micropapillary and solid histological subtype on patients undergoing curative resection for stage I lung adenocarcinoma according to the extent of pulmonary resection and lymph node assessment","volume":"168","author":"Jeon","year":"2022","journal-title":"Lung Cancer"},{"issue":"30","key":"10.1016\/j.eclinm.2025.103282_bib6","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1111\/1759-7714.15087","article-title":"Lung adenocarcinoma with micropapillary and solid patterns: recurrence rate and trends","volume":"14","author":"Takeno","year":"2023","journal-title":"Thorac Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103282_bib7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00432-020-03444-y","article-title":"Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China","volume":"147","author":"Zheng","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"30","key":"10.1016\/j.eclinm.2025.103282_bib8","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2014.58.8335","article-title":"Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection","volume":"33","author":"Tsao","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103282_bib9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non\u2013small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"Jr","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103282_bib10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103282_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103282_bib12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10308","key":"10.1016\/j.eclinm.2025.103282_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103282_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103282_bib15","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103282_bib16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s43018-021-00259-9","article-title":"Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms","volume":"2","author":"Lehti\u00f6","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.eclinm.2025.103282_bib17","article-title":"Integrated analysis of genomic and immunological features in lung adenocarcinoma with micropapillary component","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103282_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jtho.2018.09.028","article-title":"Cribriform subtype is an independent predictor of recurrence and survival after adjustment for the eighth edition of TNM staging system in patients with resected lung adenocarcinoma","volume":"14","author":"Kadota","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103282_bib19","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.jtho.2018.09.012","article-title":"Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations","volume":"13","author":"Toki","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103282_bib20","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1038\/s41467-021-26362-0","article-title":"Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer","volume":"12","author":"Cho","year":"2021","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103282_bib21","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103282_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-A meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103282_bib23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103282_bib24","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.eclinm.2025.103282_bib25","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (radiant): a randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.eclinm.2025.103282_bib26","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.22.00428","article-title":"Updated overall survival and exploratory analysis from randomized, phase II EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage IIIA epidermal growth factor Receptor+ non-small-cell lung cancer","volume":"40","author":"Yue","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103282_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.21.01729","article-title":"Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT)","volume":"40","author":"Tada","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103282_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103282_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.18.00131","article-title":"SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"37","author":"Pennell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103282_bib30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103282_bib31","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2023.0459","article-title":"Adjuvant treatments for surgically resected non\u2013small cell lung cancer harboring EGFR mutations: a review","volume":"9","author":"Passaro","year":"2023","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103282_bib32","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","article-title":"Corticosteroids and cancer immunotherapy","volume":"29","author":"Goodman","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:51:00Z","timestamp":1760215860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025002147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"alternative-id":["S2589537025002147"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103282","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103282"}}